Trial intelligence / Profile preview

Elecoglipron vs placebo in adults with type 2 diabetes mellitus on background insulin and other glucose-lowering medications (Eluminate-3)

jRCT2031260262Recruiting

Sponsor
AstraZeneca
Start
Jul 2026
Modality
Small Molecules
01

Overview

Randomised trial of elecoglipron in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in Hemoglobin A1c (HbA1c). Started Jul 2026; status: recruiting.

02

Drugs

elecoglipron
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on jRCT2031260262.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2031260262.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call